M.D., CEO, InnVentis
Thomas Wilckensis a medical doctor and entrepreneur. Dr. Wilckens is also the founder of the LinkedIn group Precision Medicine Insight. Prior to InnVentis, he was an associate at deep innovation GmbH. In 1998, he founded a drug discovery company as CEO/CSO with a focus on inflammatory and metabolic diseases. Thomas obtained his MD at the Ludwig-Maximilian University in Munich and started his research career as a scholar of the Max-Planck Society and the Max-Kade Foundation in New York. He held several post-doctorate positions at leading academic institutions before becoming an entrepreneur.Aside from his work in Precision Medicine he developed a novel concept for value creation in research intensive industries; i.e. “Symbiotic Innovation”.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: Interpreting human DNA and predicting the molecular effects of genetic variation will aid in the understanding of human disease and is expected to increasingly provide personalized insights on health risks and recommended disease treatment. The rapid commercialization of AI/machine learning and big data is well positioned to over time change disease diagnosis and management.